# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|-------|-------|
| QA Report ID | QA-PP-0233|
| Population Package | PP-0233 |
| Title | Clinical Genomics |
| Version | 1.0.0 |
| Review Status | PASS |

---

# Layer 1 — Content QA

| Criterion | Result |
|-----------|--------|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| Clinical genomic workflow covered | PASS |
| Test selection covered | PASS |
| Specimen/assay considerations covered | PASS |
| Germline vs somatic distinction covered | PASS |
| Pathology integration covered | PASS |
| Molecular pathology report covered | PASS |
| Molecular tumor board covered | PASS |
| Limitations and uncertainty covered | PASS |
| Negative-result boundary covered | PASS |
| Common misconceptions addressed | PASS |
| Key messages included | PASS |
| Downstream boundaries preserved | PASS |

---

# Layer 2 — Clinical QA

| Criterion | Result |
|-----------|--------|
| Scientifically accurate | PASS |
| Consistent with ESMO/ASCO genomic-testing framework | PASS |
| Consistent with NCCN gastric-cancer molecular-testing context | PASS |
| Consistent with NCI genomic-testing complexity framework | PASS |
| Appropriate clinical-genomics definition | PASS |
| Appropriate test-selection framing | PASS |
| Appropriate specimen/assay framing | PASS |
| Appropriate germline vs somatic distinction | PASS |
| Appropriate pathology integration | PASS |
| Appropriate molecular-tumor-board framing | PASS |
| Appropriate limitation/uncertainty framing | PASS |
| Negative result not overinterpreted | PASS |
| No unsupported treatment recommendation | PASS |
| No disease-specific biomarker algorithm | PASS |
| No unsafe medical advice | PASS |

---

# Layer 3 — Educational QA

| Criterion | Result |
|-----------|--------|
| Plain language | PASS |
| Patient-friendly wording | PASS |
| Medical terminology explained | PASS |
| One concept per paragraph | PASS |
| Short paragraphs | PASS |
| Logical clinical flow | PASS |
| Patient Explanation included | PASS |
| Clinical Importance included | PASS |
| Key Concepts included | PASS |
| Common Misconceptions included | PASS |
| Key Messages included | PASS |
| Uncertainty appropriately communicated | PASS |
| No unnecessary technical detail | PASS |

---

# Layer 4 — Governance QA

| Criterion | Result |
|-----------|--------|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| QA Report completed | PASS |
| Evidence traceability complete | PASS |
| Scope boundary defined | PASS |
| Knowledge Graph complete | PASS |
| Prerequisites defined | PASS |
| Related packages defined | PASS |
| Next package defined | PASS |
| Versioning complete | PASS |
| Repository structure compliant | PASS |
| Gold Specification alignment | PASS |
| Four-artifact package complete | PASS |

---

# Clinical Safety Review

| Item | Result |
|------|--------|
| No individualized genomic testing recommendation | PASS |
| No individualized treatment recommendation | PASS |
| No drug selection algorithm | PASS |
| No disease-specific biomarker algorithm | PASS |
| No detailed sequencing methodology | PASS |
| No detailed variant interpretation | PASS |
| No ACMG/AMP classification methodology | PASS |
| Germline testing kept conceptual | PASS |
| Somatic testing kept conceptual | PASS |
| Genomic result not presented as standalone diagnosis | PASS |
| Genomic finding not presented as automatic treatment selection | PASS |
| Negative result not presented as complete exclusion of genomic abnormality | PASS |
| Molecular tumor board not presented as a universal workflow | PASS |
| Qualified professional interpretation appropriately emphasized | PASS |

---

# Educational Boundary Review

The Population Package remains within the locked atomic scope.

## Included

- What clinical genomics is.
- Why genomic information matters in cancer care.
- Clinical genomic workflow.
- Test selection.
- Specimen and assay considerations.
- Genomic alteration categories at conceptual level.
- Pathology integration.
- Germline vs somatic concepts.
- Diagnostic/classification, prognostic and predictive roles at conceptual level.
- Molecular pathology reports.
- Molecular tumor boards.
- Assay limitations.
- Negative-result interpretation.
- What genomic results can and cannot tell patients.

## Excluded

- Detailed sequencing technology.
- NGS/WGS/WES/RNA-sequencing methodology.
- Detailed gene-panel methodology.
- Variant interpretation.
- Variant classification.
- ACMG/AMP evidence criteria.
- Genetic counseling workflow.
- Germline testing workflow.
- Somatic testing workflow.
- Disease-specific biomarker testing.
- ctDNA/liquid biopsy methodology.
- Treatment algorithms.

The **Atomic Knowledge Principle** has been preserved.

---

# Evidence Traceability Review

## 1. Clinical genomics competencies

The ESMO/ASCO Global Curriculum identifies molecular/genomic competencies including selection of appropriate molecular tests based on patient needs and tumor histology, understanding DNA/RNA/protein requirements, recognizing assay scope and limitations, interpreting molecular pathology reports with pathologists/clinical geneticists when needed, and contextualizing cases in a molecular tumor board.

Source: ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology, Edition 2023. fileciteturn67file1

---

## 2. Gastric-cancer molecular-testing context

NCCN Gastric Cancer Version 2.2026 places biomarker testing and molecular testing within the principles of pathologic review and biomarker testing. It describes IHC/ISH/targeted PCR, selected PCR/NGS applications, and broader NGS in selected circumstances, while also addressing ctDNA in specific clinical contexts.

Source: NCCN Guidelines Version 2.2026, GAST-B. fileciteturn68file0

---

## 3. Genomic-testing complexity and professional involvement

NCI's Cancer Genetics Risk Assessment and Counseling PDQ notes the complexity of genomic testing and interpretation and supports involvement of qualified professionals in test ordering and interpretation. It also discusses informed consent as an important part of genetic-testing processes.

Source: NCI Cancer Genetics Risk Assessment and Counseling (PDQ). fileciteturn65file14

---

## 4. Locked PP-0233 scope

The PP-0233 Discussion Batch explicitly defines the package as a conceptual clinical framework for using genomic information, with inclusion of test selection, pathology integration, germline/somatic concepts, limitations, and molecular tumor-board context, while excluding detailed sequencing technologies, variant interpretation/classification, genetic counseling workflows, disease-specific biomarker testing, and treatment algorithms.

Source: Locked PP-0233 Discussion Batch. fileciteturn66file5

---

# Package Completeness Review

| Required Artifact | Status |
|-------------------|--------|
| 01_CKO.md | COMPLETE |
| 02_Knowledge_Passport.md | COMPLETE |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | COMPLETE |
| 04_QA_REPORT.md | COMPLETE |

---

# Reviewer Notes

PP-0233 is positioned as the **clinical-use hub node** for genomic information.

Its central architecture is:

**clinical question**
→ **test selection**
→ **specimen**
→ **genomic finding**
→ **interpretation/classification**
→ **pathology + clinical integration**
→ **clinical use**

The package deliberately maintains the following boundaries:

- Clinical Genomics ≠ NGS methodology.
- Clinical Genomics ≠ WGS/WES/RNA-sequencing methodology.
- Clinical Genomics ≠ Variant Interpretation.
- Clinical Genomics ≠ Variant Classification.
- Clinical Genomics ≠ Germline Genetic Testing.
- Clinical Genomics ≠ Somatic Genetic Testing.
- Clinical Genomics ≠ biomarker-specific testing.
- Clinical Genomics ≠ treatment algorithm.

This positioning makes PP-0107 a central bridge between molecular testing and downstream interpretation/classification and clinical application.

---

# Final Quality Decision

## PASS

PP-0233 satisfies the locked **Gold Population Package Specification v1.0**.

Approved as the official Population Package for:

> **PP-0233 — Clinical Genomics**

Repository Status: **Ready**.

---

# Revision History

| Version | Date | Summary |
|----------|------|---------|
| 1.0.0 | 2026-08-08 | Revised Gold Release — expanded to match approved Gold package depth and locked PP-0233 scope |
